AVERTEAX by Camellix, LLC
Dosage form: cream
Ingredients: BENZYL ALCOHOL 10mg in 1g
Labeler: Camellix, LLC
NDC Code: 54866-002
Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.
Active ingredient Purpose
Benzyl Alcohol (1.0%) Cold Sores & Fever blisters
Treats cold sores and fever blisters, a vesicle that occurs at the junction of the mucous membrane and the skin on the lips or nose and is caused by the virus herpes simplex, type 1.
If condition worsens or does not improve after regular use of the product as directed, consult a doctor.
If swallowed, contact a doctor.
For external use only.
For the temporary relief of pain and itching of cold sores and fever blisters, apply AverTeaX ointment directly on the affected area throughout the day as needed. To achieve best result, apply at the frist sign of symptons (redness, tingling, tightness, or itching.)
If illergic to any ingridient of the product.
Indications are for pain and itching associated with fever blisters and cold sores.
For the temporary Relief of Pain and itching associated with fever blisters and cold sores.
If allergic to any ingredient of the product.
- Keep out of reach of children.
- If swallowed, contact a doctor.
Ultrez 10 (Carbopol), Cetyl Alcohol (Powder Form), Stearic Acid, E. Glycol Stearate (EGMS), Glyceryl Stearate (GMS), Safflower Oil, Propylene Glycol USP, Glycerin (USP Grade) 99.7%, PMX-200 Silicone Fluid, Euxyl PE 9010 (0.5% - 1.0%), Aloe Vera, EGCG (Epigallocatechin-3-Gallate, Extracted from Green Tea) Stearate, EGCG Palmitate, Eucalyptus oil, Sodium Hyaluronate (Hyaluronic Acid), Lutein 10% (Marigold Ext. 10%), TEA (Triethanolamine)(99%).
AVERTEAX TOPICAL OINTMENT COLD SORES AND FEVER BLISTERS TREATMENT DISTRIBUTED BY CAMELLIX MADE IN USA
benzyl alcohol cream
|Labeler - Camellix, LLC (968429386)|
|Star Health and Beauty, LLC||013506838||manufacture(54866-002)|
Medically reviewed on Mar 7, 2018